Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 42, Issue 12, Pages 3670-3677Publisher
WILEY
DOI: 10.1002/hed.26432
Keywords
bolus cisplatin; chemoradiation; head and neck cancer; patient reported outcome; weekly cisplatin
Categories
Ask authors/readers for more resources
Background Patient Reported Outcome (PRO) data comparing bolus (B-CP) with weekly (W-CP) cisplatin concurrent with radiation are lacking. Methods We performed a retrospective study comparing PRO among 99 patients with head and neck radiation, 26% who received concurrent B-CP and 73% treated with W-CP. Results W-CP patients had a higher Charlson comorbidity index (CCI) (P= .004). There were no differences in median cisplatin dose, PROs, percutaneous endoscopic gastrostomy (PEG) dependence or hospitalization between arms. Patients with a greater decline in their self-reported dysphagia score were more often PEG dependent at the end of radiation therapy (P= .03). There was also a trend toward PEG dependence with a higher maximum dysphagia score and greater change in aspiration score (P= .06). The maximum decline in white cell count and absolute neutrophil count were greater in the W-CP group (P= .04,P= .01). Conclusion Both B-CP and W-CP are well tolerated. PROs do not suggest a benefit to W-CP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available